heart failure Archives - CVIA Journal

Cardiac Magnetic Resonance Imaging in Heart Failure

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Heart failure (HF) is a clinical syndrome with a wide variety of clinical presentations, pathophysiologies, and natural histories. HF is becoming more prevalent globally, thus increasing effects on healthcare systems. Cardiac magnetic resonance (CMR) imaging is a valuable tool for better understanding HF and its prognosis.

The commonly used reference standard of CMR cine imaging provides accurate assessment of chamber size and function. Phase contrast imaging can be used to assess the degree of valvular regurgitation and complex flow patterns. Stress perfusion imaging can detect subtle areas of ischemia and microvascular dysfunction.

(more…)

Heart Failure Registries in Asia – What Have We Learned?

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Heart Failure (HF) is one of the leading problems in cardiology practice today. Acute decompensated heart failure (ADHF) is a significant cause of mortality and morbidity worldwide, and this is more relevant in the Asian subcontinent with a high population burden.

Various regional registries in Asia have given us valuable insight into the aetiology and outcomes in this context. Though there are regional differences, it is clear from the review carried out in this paper that HF affects a much younger population.

(more…)

Overview of Injectable Hydrogels for the Treatment of Myocardial Infarction

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Myocardial infarction (MI) triggers adverse remodeling mechanisms, thus leading to heart failure. Since the application of biomaterial-based scaffolds emerged as a viable approach for providing mechanical support and promoting cell growth, (more…)

Transcatheter Aortic Valve Replacement in Patients ≥80 and <80 Years of Age with Aortic Valve Stenosis at Moderate Surgical Risk: Findings from an Observational Study in the Vietnamese Population

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The increasing number of elderly patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement (TAVR) has prompted concerns regarding their clinical outcomes compared with the younger population. This study evaluated the outcomes of TAVR on the basis (more…)

The Development of Ventricular Assist Devices over the Past 30 Years: A Bibliometric Analysis

Announcing a new article publication for Cardiovascular Innovations and Applications journal.

A large gap exists between the needs of patients with end-stage heart failure and the number of gold-standard heart transplants. Over the past 30 years, a revolutionary treatment strategy using ventricular assist devices (VADs) has rapidly developed and become widely used in clinical practice. However, few analyses have assessed the application and publication trends in the VAD field.

The authors of this article used the Web of Science core collection to identify VAD research published between 1992 and 2022. Analysis and data visualization was performed with CiteSpace, Scimago Graphica, and VOSviewer.

13,274 articles published in 1129 journals were identified, describing work from 6351 institutions in 86 countries. Among them, the United States contributed the most to VAD research, and almost all the top ten authors and institutions contributing to VAD research were from the United States.

In the past 5 years, VAD research has focused on right heart failure, outcomes, effects and risk factors, societies of surgeons, and clinical guidelines. Because of the large number of patients with heart failure, it is expected that VAD development to peak in the next decade.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0088

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Zhou Liu, Siyue Zheng and Yazhe Zhang et al. The Development of Ventricular Assist Devices over the Past 30 Years: A Bibliometric Analysis. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0088

Associations of Heart Failure Onset Age with All-Cause Mortality: The Kailuan Study

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at investigating the correlations between heart failure onset age and all-cause mortality.

The study examined 186,249 patients treated at Kailuan Group hospitals who underwent medical evaluations between 2006 and 2018. Biennial health assessments were conducted, and, as of December 31, 2020, 4022 heart failure instances were identified. For each patient with new-onset heart failure, four control participants were randomly selected, matched for age (within ±1 year) and sex. Cox regression models were used to calculate the hazard ratios of all-cause mortality across age groups.

The median follow-up duration was 5.25 (2.65, 8.63) years. All-cause mortality occurred in 1783 participants in the new-onset heart failure group and 2633 participants in in the control group. Refined multivariable Cox regression analysis revealed that patients with heart failure under 55 years of age had the highest relative mortality risk, with an HR (95% CI) 6.86 (4.42–10.64) with respect to their matched controls. Moreover, the relative mortality risk systematically decreased with increasing age of heart failure onset: HR (95% CI) 4.70 (3.73–5.92) for ages 55–64, HR (95% CI) 3.23 (3.73–3.81) for ages 65–74, and HR (95% CI) 1.69 (1.48–1.94) for 75 years or older.

Heart failure significantly elevates the risk of all-cause mortality, and the risk is more pronounced with earlier manifestation of the condition.

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Wei Li, Haibo Gao and Xuemei Zhao et al. Associations of Heart Failure Onset Age with All-Cause Mortality: The Kailuan Study. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0085

Heart Failure Guideline Directed Medical Therapy: Which One and When?

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Over the past several decades, major strides have been made in the management of heart failure with reduced ejection fraction (HFrEF). The 2022 AHA/ACC/HFSA guidelines recommend four drug classes in all patients with symptomatic HFrEF. This guideline directed therapy (GDMT) includes renin angiotensin receptor (RAAS) blockade, preferentially with angiotensin receptor neprilysin inhibitors (ARNI), beta blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter inhibitors (SGLT2i). An optimal GDMT regimen has been estimated to achieve greater than 70% mortality benefit. Unfortunately, most patients with HFrEF are not taking the appropriate medications or doses. Several clinical challenges and questions arise when attempting to initiate and titrate these medications. Although the guidelines offer several suggestions for this process, each patient’s hemodynamic profile varies markedly, thus making development of a uniform algorithm difficult. As new trials are performed, greater emphasis is being placed on more aggressive titration of GDMT. Most importantly, initiation of GDMT should start during hospitalization and continue with close outpatient follow-up. Identifying each patient profile, defined by volume status, blood pressure, heart rate, and kidney function, dictates the order and timing of GDMT titration.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0077

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Michelle Dimza and Juan M. Aranda. Heart Failure Guideline Directed Medical Therapy: Which One and When?. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0077

Left Bundle Branch Ablation Guided by a Three-Dimensional Mapping System: A Novel Method for Establishing a Heart Failure Animal Model

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Few studies have been conducted to establish animal models of left bundle branch block by using three-dimensional mapping systems. This research reported by this article was aimed at creating a canine left bundle branch block model by using a three-dimensional mapping system.

A three-dimensional mapping system was used to map and ablate the left bundle branch in beagles. Ten canines underwent radiofrequency ablation, among which left bundle branch block was successfully established in eight, one experienced ventricular fibrillation, and one developed third-degree atrioventricular block. The maximum HV interval measured within the left ventricle was 29.00 ± 2.93 ms, and the LBP-V interval at the ablation site was 20.63 ± 2.77 ms. The LBP-V interval at the ablation target was 71.08% of the maximum HV interval.

This three-dimensional mapping system is a reliable and effective guide for ablation of the left bundle branch in dogs.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0066

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Pengkang He, Han Jin and Yiran Hu et al. Left Bundle Branch Ablation Guided by a Three-Dimensional Mapping System: A Novel Method for Establishing a Heart Failure Animal Model. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0066

Heart Failure with Preserved Ejection Fraction: Important Things to Know About the Stiff Heart

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Heart failure remains a leading cause of morbidity, mortality, and healthcare expenditure, both nationally and worldwide. In the current era of cardiovascular disease, heart failure with preserved ejection fraction (HFpEF) is recognized to be a clinical entity with equal prevalence and similar morbidity and mortality rates to the traditional syndrome of heart failure with reduced ejection fraction (HFrEF), yet with distinct differences. The HFpEF phenotype presents many challenges, beginning with accurate diagnosis, because the differential diagnosis for patients with symptoms of dyspnea in the context of a normal ejection fraction remains very broad. Moreover, although numerous medical and device-based therapies have been identified in the past several decades to improve clinical outcomes in HFrEF, treatment options for HFpEF with similar efficacy are lacking. Familiarity with the current understanding of the underlying pathophysiology of HFpEF can aid in overcoming some of these challenges, although the mechanisms resulting in HFpEF and the proper therapies remain incompletely defined.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0058

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Juan R. Vilaro. Heart Failure with Preserved Ejection Fraction: Important Things to Know About the Stiff Heart. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0058

Sex Differences in Quality of Life and Clinical Outcomes in Patients with Heart Failure

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Heart failure (HF) is generally associated with poor quality of life (QoL). Limited data are available characterizing health-related QoL (HRQL) in Chinese patients with HF.

The authors of this article used the Minnesota Living with Heart Failure Questionnaire (MLHFQ) to record QoL in 4082 patients with HF from China who were followed up over 12 months in the Heart Failure Registry of Patient Outcomes (HERO) study. Baseline HRQL and differences in QoL between women and men with heart failure were compared. Multivariable Cox regression with adjustment for variables was used to assess the association between MLHFQ summary

At baseline, the mean MLHFQ in the overall population was 42.9 ± 19.57; the scores for physical and emotional domains were 22.0 ± 8.69 and 8.66 ± 6.08, respectively. Women had a higher (poorer) MLHFQ summary score (44.27 ± 19.13) than men (41.63 ± 19.90) (P<0.001). Female patients also had higher MLHFQ physical and emotional scores than male patients (P<0.001). The specific scores of the questionnaire were higher in women than men. NYHA class was the strongest independent predictor of MLHFQ score (β=6.12 unit increment; P<0.001). Sex was not independently associated with higher MLHFQ scores after multivariable adjustments. The 12-month mortality in the overall cohort was 19.6%, the hospitalization rate was 24.4%, and the composite endpoint was 40.15%. A 10-point increase in MLHFQ score was associated with higher risk of mortality (female and male HRs=1.19 [95% CI 1.12–1.26]; P<0.001 and 1.18 [95% CI 1.12–1.24]; P<0.001, respectively) and composite outcomes (HRs=1.08 [95% CI 1.04–1.13]; P<0.001 and 1.11 [95% CI 1.07–1.14]; P<0.001, respectively). Females did not show a significant association between HRQL and hospitalization (HR=1.04 [95% CI 0.99–1.09]; P=0.107).

Quality of life was largely poorer in women than men, but was similar between sexes in terms of physical burden and emotional limitation. HRQL is an independent predictor of all-cause death and HF hospitalization in patients with HF.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0046

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Liu Jingxuan, Zhou Lu and Wang Xuesi et al. Sex Differences in Quality of Life and Clinical Outcomes in Patients with Heart Failure. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0046

Tag: heart failure